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Abstract
Gram-positive streptococci are non-motile, chain-forming bacteria commonly found in the normal oral and
bowel flora of warm-blooded animals. Over the past decade, a proteomic approach combining 2-DE and
MS has been used to systematically map the cellular, surface-associated and secreted proteins of human
pathogenic streptococcal species. The public availability of complete streptococcal genomic sequences
and the amalgamation of proteomic, genomic and bioinformatic technologies have recently facilitated the
identification of novel streptococcal vaccine candidate antigens and therapeutic agents. The objective of
this review is to examine the constituents of the streptococcal cell wall and secreted proteome, the
mechanisms of transport of surface and secreted proteins, and describe the current methodologies
employed for the identification of novel surface-displayed proteins and potential vaccine antigens.
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Abstract
Gram-positive streptococci are non-motile, chain-forming bacteria commonly found in
the normal oral and bowel flora of warm-blooded animals. Over the past decade, a
proteomic approach combining 2-DE and MS has been used to systematically map the
cellular, surface-associated and secreted proteins of human pathogenic streptococcal
species. The public availability of complete streptococcal genomic sequences and the
amalgamation of proteomic, genomic and bioinformatic technologies have recently
facilitated the identification of novel streptococcal vaccine candidate antigens and
therapeutic agents. The objective of this review is to examine the constituents of the
streptococcal cell wall and secreted proteome, the mechanisms of transport of surface
and secreted proteins, and describe the current methodologies employed for the
identification of novel surface-displayed proteins and potential vaccine antigens.
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1

Introduction – Streptococcal infection of humans

The Genus Streptococcus consists of numerous Gram-positive, non-motile, chainforming cocci commonly found in the normal oral and bowel flora of warm-blooded
animals. Streptococci are a diverse group of bacteria capable of colonizing and infecting
a broad spectrum of host organisms and tissues. The Genus is comprised of 49 species
and 8 subspecies of which 35 have been isolated as a source of infection in humans [1].
Pathogenic streptococcal species fall into three broad categories: pathogenic species
commonly causing infection in humans; commensal species and zoonotic species which
under the right conditions cause opportunistic infection in humans. Streptococcus
pyogenes (group A Streptococcus; GAS), S. agalactiae (group B Streptococcus; GBS), S.
pneumoniae, and S. mutans are pathogenic streptococcal species commonly causing
infection in humans (Table 1). GAS colonizes the mucosa of the respiratory tract and skin
causing, most commonly, pharyngitis and pyoderma. When S. pyogenes colonizes
normally sterile tissues severe invasive disease may result [2, 3]. GBS is a commensal
bacterium colonizing the intestinal tract of a significant proportion of the human
population; it is also a pathogen that invades a number of different host compartments
and may cause severe neonatal infections [4-7]. S. pneumoniae is a commensal
streptococcal species carried asymptomatically in up to 60% of the population. The
pneumococcus is also responsible for a significant burden of disease in children under the
age of 2 years, the elderly and patients with immunodeficiencies causing diseases
including pneumonia, meningitis, and otitis media [8, 9]. S. mutans is the main causative
agent of human dental caries, one of the most common infectious diseases afflicting
humans [10]. Infection by commensal and zoonotic streptococcal species occur primarily
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in immunocompromised individuals and the elderly [11-15]. Commensal organisms
colonizing the oral mucosa, the surface of teeth (organisms of the groups S. mitis, S.
mutans, S. salivarius, S. anginosus) and other mucosal niches (S. anginosus group), may
cause infective endocarditis and have also been associated with serious suppurative
infections (Table 1) [10, 16-19]. A few species of Streptococcus with reservoirs in
animals have proven to be zoonotic, including species from horses (S. dysgalactiae subsp.
equisimilis, S. equi subsp. zooepidemicus), cattle (members of the S. bovis group), dogs
(S. canis), pigs (S. porcinus, S. suis), fish (S. iniae), and chickens (S. gallinaceus).
Zoonotic species most commonly cause invasive disease and have been associated with
toxin-mediated infections [12, 14, 20-24] (Table 1). Zoonotic streptococcal species are
primarily food borne or transmitted through cuts and abrasions [12]. Table 1 highlights
the significant burden of disease caused by human pathogenic streptococcal species.
The complete genome has been sequenced for multiple strains of S. pyogenes
[25-30], S. agalactiae [31, 32], S. pneumoniae [33, 34] and S. suis [35] and a single
strain of S. mutans [36]. The public availability of complete genome sequences
coupled with adjunct technologies such as bioinformatics tools, proteomics, MS and
N-terminal amino acid sequencing, has facilitated the compilation of comprehensive
proteomic maps and the identification of promising target antigens for inclusion into
vaccine formulations against human bacterial pathogens [37, 38]. This review will
focus on the human pathogenic streptococci and cover 1) the secreted, surface and cell
wall proteomes, 2) transport mechanisms for secreted, surface and cell wall proteins,
and 3) advances in vaccine development and the role played by genomic and
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proteomic data in informing the development of safe, efficacious, and broadly
protective vaccines.
2

Streptococcal proteomics

Several different strategies are currently employed to identify bacterial surface proteins
including: 1) an in silico genome-based strategy using algorithms such as PSORT to
search complete genome sequences for putative proteins harboring cell wall anchor
motifs and transmembrane domains; 2) the purification of surface-displayed proteins by
chemical or enzymatic methods followed by 2-DE and identification by PMF; and 3) the
cloning, expression and subsequent generation of antibodies against putative surfacedisplayed proteins for whole-cell assays and/or electron microscopic analysis to confirm
surface-localization [39]. In the majority of cases, surface-localized streptococcal proteins
are isolated either by sequential chemical extraction, or enzymatic digestion of the
peptidoglycan-containing cell wall with lysozyme or mutanolysin in an isosmotic buffer
to minimize cell rupture and contamination of the preparation with cytoplasmic proteins
[40]. The extracts are then fractionated by 2-DE, the excised protein spots digested with
trypsin, and the peptide fragments analyzed by MALDI-TOF MS or MS/MS [40]. While
this strategy has the capacity to identify anchorless cell surface proteins potentially
overlooked with a computational genome-wide screening approach [41, 42], it typically
detects a relatively small number of membrane-associated proteins [43, 44], due either to
their inherent hydrophobicity and aggregation during IEF, or their low abundance within
the cell wall [40]. To circumvent these problems, streptococcal surface proteins have
recently been mapped using the techniques of reverse vaccinology, which involve: 1) the
identification of numerous putative vaccine candidates by in silico analysis of complete
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genome sequences; 2) the cloning, over-expression and purification of each recombinant
antigen; and 3) the subsequent active immunization of mice to test for immunological
protection [45]. This strategy has been successfully used for identification of novel
antigens in S. pyogenes [46-49] and S. agalactiae [50].
Two-dimensional gel electrophoretic profiles, or reference maps, have been
generated for numerous streptococcal spp. [38, 51-56]. Basic reference maps of soluble
cytosolic proteins are routinely used to compare various strains of streptococci and
identify changes in protein expression under physiological stresses [51, 57]. Pathogenic
streptococci express a broad spectrum of multifunctional cell wall and surface-associated
proteins which facilitate adherence to and invasion of host cells, evasion of the host
immune response, and degradation of host proteins [2, 58]. Consequently, the surface
proteins of these bacteria are often important targets for vaccine development. Several
cell wall and surface-localized streptococcal antigens have been identified as promising
vaccine candidates by immunoproteomic analyses [41, 43, 44, 59-62]. Many proteins are
also secreted from the streptococcal cell surface into the extracellular milieu [38, 46, 56,
62-65]. These proteins influence host-pathogen interactions and may contribute to
disease. Gram-positive proteins destined for transport across the cytoplasmic membrane
frequently contain a hydrophobic N-terminal signal sequence [66, 67]. Curiously, a
number of secreted streptococcal proteins lack apparent secretion signal sequences [46,
56, 66]; thus the mechanism by which these proteins are transported to the bacterial cell
surface is yet to be elucidated. This section will describe the methodologies currently
employed for the identification of streptococcal surface-displayed and secreted proteins,
which represent potential vaccine antigens or therapeutic targets.
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2.1

S. pyogenes cell wall and surface-associated proteome

The initial proteomics-based identification of group A streptococcal cell wall and surfaceassociated proteins was undertaken by Cole et al. [59]. Cell wall extracts were harvested
by enzymatic digestion using a combination of lysozyme and mutanolysin. The muralytic
enzyme mutanolysin cleaves the β-1,4 linkage of the N-acetylmuramyl-Nacetylglucosamine in the glycan backbone of the highly conserved peptidoglycanpolysaccharide polymer, and is routinely used for the preparation of streptococcal
protoplasts [68, 69] and the solubilization of cell wall-associated proteins, with minimal
leakage of cytoplasmic contents [70, 71]. Mutanolysin extracts harvested from in vitro
stationary-phase cultures of three different S. pyogenes serotypes (M69, M53 and M6)
were analyzed by 2-DE and the most abundant proteins identified by in-gel tryptic
digestion and MALDI-TOF MS analysis. Interrogation of publicly available databases
containing complete GAS genomic sequences identified a total of 74 distinct proteins, 66
of which had not previously been characterized as cell wall-associated in GAS. In order
to identify the immunoreactive cell wall-associated proteins, 2-D western blots of
mutanolysin extracts were probed with pooled antisera from GAS-infected humans. This
technique identified 33 immunoreactive cell wall proteins which are presumably
expressed during the course of human infection. To determine which cell wall-associated
proteins were surface-exposed, and hence potential vaccine candidate antigens, the GAS
cell surface was biotinylated prior to mutanolysin extraction, 2-D immunoblotting and
detection of biotin-labeled proteins with a streptavidin HRP conjugate. In the aggregate,
23 cell wall-associated proteins were biotinylated and thus surface-exposed, illustrating
the usefulness of high-throughput proteomics in elucidating novel vaccine candidate
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antigens. Depending on the strain, S. pyogenes has 14-17 cell wall-associated proteins
predicted from in silico analysis of completely sequenced genomes [39, 72, 73]. The
study by Cole et al. [59] only identified 3/17 predicated cell wall-linked proteins.
Furthermore, while this proteomic approach is quantitative, the enzymatic degradation of
the bacterial cell wall may cause cell lysis and contamination of cell wall fractions with
cytoplasmic proteins [40]. However, the use of mutanolysin, lysozyme and other
biochemical methods for the extraction of surface-associated proteins followed by 2-DE,
has a distinct advantage over in silico genome searches given that a significant number of
such proteins lack N-terminal signal and C-terminal anchor sequences [43].
Rodríguez-Ortega et al. [39] identified the surface-exposed proteins of S.
pyogenes SF370 (serotype M1) by using a combination of biochemical, proteomic and
bioinformatic techniques. Whole cells were treated in situ with proteolytic enzymes
(trypsin or proteinase K individually, or in tandem) to “shave” the protruding cell surfaceassociated proteins. The released peptide fragments were purified, analyzed by nanoLC/MS/MS, and identified by searching the publicly available genome sequence of
SF370 [39]. This approach identified 68 putative surface-associated proteins, including
12 canonical cell wall proteins harboring the LPXTG cell wall-sorting motif, 11
lipoprotein family proteins, 37 transmembrane proteins, and 8 secreted proteins. Only 4
identified proteins were predicted cytosolic proteins, illustrating that digestion of
bacterial surface proteins does not rupture the cells nor release contaminating cytoplasmic
proteins [39]. PSORT topological prediction analysis and fluorescence-activated cell
sorting with protein-specific antibodies raised in mice, confirmed the surface-localization
of most identified proteins. Furthermore, the putative cell-envelope serine proteinase
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Spy0416 identified in this study was protective against virulent DSM2071 GAS challenge
in a mouse model of intranasal infection [39]. The methodology used in this study
circumvents contamination issues associated with the preparation of cell wall proteins by
conventional enzymatic methods, and provides a tool for the selective identification of
bacterial surface-exposed proteins and new vaccine candidates. This approach is also
cheaper and less labor-intensive than the in silico genome-based strategy employed by
Maione et al. [50], which involved the cloning, over-expression, and purification of 312
surface proteins of S. agalactiae, only 4 of which were protective in a mouse infection
model [74]. However, Rodríguez-Ortega et al. [39] only identified 6.5% of PSORTpredicted transmembrane proteins, suggesting that these proteins are either resistant to
protease digestion, undergo complete proteolytic degradation, are poorly expressed, are
differentially regulated, or are hidden within the bacterial cell membrane [39].
Furthermore, this investigation only utilized a single growth medium and harvested the
bacteria at a single growth phase. It is well established that the proteome of S. pyogenes
differs significantly according to growth conditions and the phase of growth, which may
influence the composition of the S. pyogenes surfaceome [45]. Of note, the SF370 M1
serotype differs significantly genetically from the globally disseminated M1T1 clone - the
serotype responsible for a substantial proportion of severe invasive diseases, such as
necrotizing fasciitis and streptococcal toxic shock syndrome [56, 75-77].
Severin and associates [40] also directly digested the surface-exposed proteins of
S. pyogenes SF370 (serotype M1) with trypsin and identified the resultant peptide
fragments by multidimensional nano-LC-MS/MS. However, in contrast to RodríguezOrtega et al. [39], surface-associated proteins were harvested from cells grown to early-
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and late-exponential phase to account for the well characterized growth phase-dependent
differences in protein synthesis [52]. In silico genomic analysis was also employed to
identify putative cell surface-associated proteins. This proteomic approach identified 79
surface-associated proteins, including 33 proteins not previously characterized as being
surface-localized in S. pyogenes. These proteins included 4/17 predicted cell wall anchor
motif-containing proteins, 12/27 predicted lipoproteins, 9 secreted proteins, 22
membrane-associated proteins, 1 bacteriophage-associated protein, and 21 proteins
traditionally classified as cytoplasmic. In the aggregate, 58 of the 79 proteins identified in
this study were predicted to be surface-localized by computer-assisted sequence analyses
with well established algorithms. Cell surface-localization of some proteins (12 of 16
tested) was confirmed by whole-cell ELISA using mouse antisera raised against purified
recombinant protein. One of these, putative translation elongation factor Tu, is a
traditional cytoplasmic protein involved in protein synthesis. Three hypothetical proteins
exhibited high antibody titres [40], two of which are known to elicit protection against
GAS challenge in a mouse model of infection [39, 48]. These findings suggest the
method of direct digestion of bacterial surface-exposed proteins is an efficient way to
identify putative surface antigens, which may facilitate the development of a safe and
efficacious human vaccine. To avoid potential contamination of surface-exposed proteins
with cytoplasmic proteins, whole cell tryptic digestion was performed in a buffer
supplemented with D-arabinose, which promotes the formation of protoplasts in the event
of cell wall hydrolysis. Cryo-field emission scanning electron microscopic analyses,
viable cell counts, and the absence of the abundant cytoplasmic proteins lactate
dehydrogenase and pyruvate oxidase, confirmed the integrity of whole-cells following

10

trypsin treatment [40]. Surprisingly, only 33 surface-exposed proteins were common to
this study and the work of Rodríguez-Ortega et al. [39]. The differences in algorithms
used for bioinformatic analyses, the stringency of matched peptides and protein
identification, as well as differences in growth-phase, may account for this disparity [40].
2.2

Secreted group A streptococcal proteome

Several studies of the S. pyogenes proteome have focused on proteins released into the
extracellular environment [46, 56, 64, 65]. Streptococcal pyrogenic exotoxin B (SpeB) is
an extracellular and surface-associated cysteine protease virulence factor produced by
most GAS strains [78]. Genetic inactivation of the speB gene or chemical inactivation of
SpeB with the cysteine protease inhibitor E64, reveals that SpeB can efficiently degrade
the majority of proteins in the secreted GAS proteome [46, 63, 79]. Using 2-DE and
amino-terminal amino acid sequencing, Lei et al. [46] identified forty-four distinct
proteins in the culture supernatants of two isogenic speB mutant GAS strains of serotypes
M1 and M3, grown in vitro at 37°C. Many of these proteins had not previously been
described in GAS and only sixteen of these had apparent secretion signal sequences,
which included virulence factors streptolysin O, M protein, SpeA, SIC, and streptokinase.
The remaining twenty-seven extracellular proteins identified had no apparent secretion
signal sequences and included traditional cytosolic proteins such as glycolytic enzymes,
chaperonins, protein translation factors, urea cycle proteins, ribosomal proteins, a DNA
binding protein, and general housekeeping enzymes. Following 2-D western blot analyses
with sera from GAS-infected mice and humans, many of the secreted proteins were found
to be immunogenic and thus expressed during course of human infection [46]. The
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absence of a signal peptide and LPXTG motif suggests that an alternative secretory
pathway may exist for many secreted GAS proteins.
2.3

S. pneumoniae cell wall and surface-associated proteome

An immunoproteomics-based approach was used to identify novel S. pneumoniae vaccine
candidates [44]. Enriched cell wall protein extracts from S. pneumoniae WU2 were
resolved by 2-D electrophoresis and identified by MALDI-TOF MS. Two-dimensional
western blot analysis using sera from children frequently exposed to S. pneumoniae and
healthy adults, identified 17 common immunogenic proteins, 13 of which exhibited an
age-dependent increase in antigenicity. Two of these proteins, identified as glycolytic
enzymes fructose-bisphosphate aldolase (FBA) and glyceraldehyde-3-phosphate
dehydrogenase (GAPDH), elicited cross-strain protective immunity against respiratory
challenge with virulent pneumococci in a mouse model of intranasal infection [44].
However, this investigation only identified a relatively small number of streptococcal cell
wall-associated proteins containing cell wall anchor motifs, despite bioinformatic
predictions of 14-16 in S. pneumoniae [72, 80].
Overweg and coworkers [61] isolated hydrophobic, surface-associated proteins
from S. pneumoniae strain FT231 using the N-tetradecyl-N,N-dimethylammonio-1propanesulfonate (SB14) extraction procedure [81]. Following separation by 2-DE,
individual proteins were identified by MS and N-terminal amino acid sequencing. Two of
the three proteins identified as contributing to opsonophagocytic activity in vitro included
the previously characterized pneumococcal surface protein A and the oligopeptidebinding lipoprotein. The third protein was identified as the putative proteinase maturation
protein A (PpmA). The surface localization of PpmA was confirmed using
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immunoelectron microscopy, and the opsonophagocytic antibodies raised against PpmA
were cross-reactive against several pneumococcal strains. In addition, PpmA was
required for full virulence in a mouse pneumonia model. These data suggest that PpmA
may be a suitable candidate antigen for inclusion in future pneumococcal vaccine
formulations [61]. Additionally, proteomic analysis of mutanolysin cell wall extracts
from S. pneumoniae WU2 (serotype 3) identified immunogenic proteins which may
represent future targets for pneumococcal vaccine development [41]. These include
traditional housekeeping proteins such as FBA, enolase, trigger factor, L-lactate
dehydrogenase, pyruvate kinase, and phosphoglycerate kinase (PGK).
2.4

Group B streptococcal cell wall and surface-associated proteome

A proteomic analysis was undertaken by Hughes et al. [43] to identify the most abundant
surface-associated proteins of S. agalactiae. Mutanolysin extracts of outer cell surface
proteins were separated by 2-DE and identified using MS and reverse genetic techniques.
The absence of DNA in the protein extract confirmed the absence of intracellular
contamination. In total, 27 major protein spots were identified, 6 of which were
previously unidentified in S. agalactiae, including ornithine carbamoyltransferase (OCT),
PGK, nonphosphorylating GAPDH, purine nucleoside phosphorylase, enolase, and
glucose-6-phosphate isomerase. Two of the putative surface-displayed cytoplasmic
enzymes, OCT and PGK, were cloned, over-expressed in vitro, and the purified
recombinant proteins used to raise polyclonal antisera. The antibodies were used in
subsequent whole-cell ELISAs to confirm the cell surface localization of each protein.
Passive immunization with antibodies against OCT and PGK in a mouse model of
neonatal intraperitoneal infection afforded some protection against lethal S. agalactiae
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challenge (46 and 35% survival for anti-OCT and anti-PGK, respectively, versus 64 and
2% survival for whole-cell positive control and preimmune serum, respectively),
suggesting these proteins warrant further investigation as potential vaccine candidates
[43]. Many of the anchorless surface-associated proteins identified by this proteomic
approach may not have been identified by the conventional whole-genome screening
strategy [82]. However, this method identified a relatively small number of streptococcal
wall-associated proteins containing cell wall anchor motifs [43], despite genomic
predictions of 25-35 proteins in S. agalactiae [72, 80]. Although labor intensive, this
approach is quantitative and identifies bona fide surface-associated proteins [39].
2.5

S. mutans cell membrane-associated proteome

Len et al. [38] generated proteomic reference maps for soluble cellular and extracellular
proteins of S. mutans grown in continuous culture. However, this study only identified
three proteins associated with the cellular membrane (WapA, Gbp and SpaP). Membraneassociated proteins are frequently under-represented in proteomic reference maps due
either to their low-abundance or hydrophobicity, which leads to poor solubility,
aggregation during IEF, and poor resolution on 2-D gels [83-86]. Recently, Hasona et al.
[87] undertook a systematic proteomic analysis of cytoplasmic membrane-associated
proteins in S. mutans strain UA159 by combining 2-DE and nanoelectrospray quadruple
time of flight (QTOF)-tandem MS/MS. Previously, only the cytoplasmic proteins of S.
mutans had been characterized by 2-DE [88-92]. Zuobi-Hasona et al. [85] solubilized
cellular membrane proteins from S. mutans UA159 using three different methods, arrayed
the samples by 2-DE, and identified the proteins by QTOF MS/MS. Several known
membrane- and surface-associated proteins were successfully identified, including
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enolase, glucose 6-phosphate isomerase, PGK, GAPDH, and ribosomal protein L7/L12
[85].
2.6

S. suis cell wall and surface-associated proteome

Two temperature-induced surface-associated proteins of S. suis strain I9841/1 (serotype
2) identified by a proteomic approach are highly homologous to members of the arginine
deiminase system of S. pyogenes, including an OCT protein and the virulence factor
streptococcal acid glycoprotein (SAGP) [93]. Immunoelectron microscopic analyses
using anti-S. pyogenes SAGP antiserum confirmed the localization of the S. suis SAGP
homologue, designated AdiS, on the streptococcal cell surface [93]. The surface
localization, ubiquitous distribution of the adiS gene among S. suis strains, temperatureinduced expression, and high sequence homology with the SAGP virulence factor,
suggest that AdiS may represent a temperature stress induced virulence factor in S. suis
[93].
In an attempt to identify the cell wall-associated proteins of S. suis harboring a Cterminal LPXTG motif, guanidine-insoluble mutanolysin-released cell wall proteins from
strain NCTC 10234 (serotype 2) deficient in srtA, a sortase-encoding gene, were analyzed
by 2-DE. Comparison with the parent strain identified 15 missing proteins in the cell
wall-linked protein file of the srtA mutant, which were restored upon complementation
with cloned S. mutans srtA. Four of these proteins were identified by N-terminal amino
acid sequence analysis and their putative genes were predicted to possess an N-terminal
signal sequence and a C-terminal LPXTG motif. The proteomics-based strategy utilized
in this study overcomes the lack of complete S. suis genome sequence data for in silico
bioinformatic screening of novel cell wall-associated proteins [94].
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3

Protein export

Surface-exposed and secreted proteins are key players during the infectious process of
streptococci and may serve as protective antigens for vaccine development. The first step
in exporting proteins to the cell surface is the trafficking of protein across the cellular
membrane. Several distinct pathways have been identified in Gram-positive bacteria for
protein export from the cytoplasm via controlled translocation channels such as the
general secretory (Sec) pathway, twin-arginine translocation (TAT) pathway, a pilispecific secretion/assembly pathway, and the “ExPortal” system [95].
3.1

Sec pathway

The majority of Gram-positive bacterial proteins, including streptococcal proteins, are
exported by the highly conserved Sec pathway (Figure 1). This pathway has been
extensively characterised [95] and will not be further described in this review.
3.2

TAT pathway

The TAT pathway translocates folded proteins harbouring a distinctive twin-arginine
motif in the signal peptide of the corresponding precursor proteins [95] and comprises the
three functionally distinct membrane proteins, TatA, TatB, and TatC (Figure 1) [96].
While TatB and TatC are involved in the specific recognition of the substrate, TatA may
be the major pore-forming component [96]. Homologs of TatA and TatC have been
identified in S. thermophilus and these homologs appear to be absent in other streptococci
[97].
3.3

Pili-specific secretion/assembly pathway

Pili in Gram-positive pathogens are formed by covalent polymerization of adhesive pilin
subunits and are secreted through the cell membrane by the Sec machinery [67] (Figure
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1). Sortase, as described below, is required for the polymerization of the pili subunits and
attachment of pili to the bacterial cell surface. Pilin subunit proteins are synthesized as
precursors carrying N-terminal signal peptide and C-terminal LPXTG motif [67]. The
identification of pili in streptococcal species has only been recently published [98-100].
Pili of S. pyogenes serotype M1 promote adhesion to human tonsil epithelium and
primary human keratinocytes and in the formation of biofilm [101, 102], while the pili
proteins of S. agalactiae facilitate adherence and invasion of brain endothelium [103].
The pilus operons promoting synthesis and assembly of pili are found in genomic islands
such as the FCT pathogenicity island in S. pyogenes [98], the rlrA pathogenicity island in
S. pneumoniae [100, 104], and in novel genomic islands in S. agalactiae [99, 105].
3.4

Exportal

A distinct microdomain termed the ExPortal has been identified in S. pyogenes which
contains a high concentration of the Sec translocon component SecA [106]. Immunogold
electron microscopic analyses demonstrate the location of the ExPortal to a hemispherical
position distal to either cell pole [106]. S. pyogenes secretes the cysteine protease SpeB
exclusively through the ExPortal and its maturation protein HtrA co-localize with SecA
at this domain (Figure 1) [106, 107]. However, in a recent study using SecA antiserum, it
has been demonstrated that SecA was distributed throughout the periphery of the surface
of S. pyogenes and was not confined to the single ExPortal as described in earlier studies
[108]. Such differences may relate to the different M types used in each study.
4

Protein retention

Retention of streptococcal secreted proteins to the cell surface can be achieved by one of
the following mechanisms: 1) covalent attachment to the cell wall by sortase enzymes; 2)
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non-covalent association with other surface molecules such as teichoic acids and
lipoteichoic acids; and 3) direct anchorage to the cytoplasmic membrane as lipoproteins.
4.1

Covalently bound cell wall proteins

Sortase (SrtA) is a membrane-associated transpeptidase that recognizes the C-terminal
sortase recognition motif LPXTG [109]. SrtA homologs are responsible for anchoring the
majority of LPXTG containing streptococcal surface proteins and have been identified in
the genomes of S. pyogenes [110], S. gordonii [111], S. mutans [112], S. suis [94], S.
pneumoniae [113], S. agalactiae [114], and S. sanguinis [115]. More than one sortase
gene has been indentified in S. pyogenes [110], S. pneumoniae [116] and S. suis [117]. A
class C sortase (SrtC2) has been recently identified in S. pyogenes which anchors a
protein (Orf100) containing a QVPTGV motif to the cell surface [118].
4.2

Non-covalently bound cell wall proteins

The choline-binding proteins (CBPs) of S. pneumoniae and other Gram-positive bacteria
all contain structurally similar choline-binding domains, which are composed of multiple
copies of a repeat segment of around 20 amino acid residues referred to as the cholinebinding domain [119]. The choline-binding motif has also been identified in other
exported proteins, including the glucan-binding protein of S. mutans [120] and
glycosyltransferases of S. mutans and S. downei [121, 122].
4.3

Lipoproteins

Lipoproteins contain a distinctive lipoprotein signal motif LXXC in the N-terminus
region which is subsequently cleaved by the type II signal peptidase and covalently
attached to the palmitic acid in the cell membrane [123]. Several members of this family
of proteins have been identified in S. pneumoniae including PpmA, SlrA, PsaA, PiaA,
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and PiuA [123, 124]. Further, putative surface-associated lipoproteins have also been
identified by surface proteome studies in S. pyogenes [39, 40, 59].
4.4

Anchorless proteins

Proteomic analyses of the streptococcal surface have revealed a number of anchorless
proteins that do not possess the classical features such as signal sequences or membraneanchor domains [39, 40, 43, 59]. Remarkably, the analysis has identified a significant
number of traditional cytoplasmic proteins commonly thought to be intracellular in
streptococci. Many of these proteins have been identified as virulence factors in
streptococci, such as the glycolytic pathway enzymes enolase and GAPDH, which have
been identified as plasminogen-binding and cell wall-associated in S. pyogenes [125-127]
and in S. pneumoniae [128].
The mechanism of translocation and retention of these proteins is not yet known.
It could be hypothesized that these proteins are either passively released during autolysis,
or that an alternative secretory pathway may exist for these proteins. Recently it has been
demonstrated that α-enolase of S. pneumoniae, which is one of the key enzymes in the
glycolytic cycle, re-associates to the cell surface by interacting with receptors on
encapsulated and unencapsulated pnuemococci [129]. This type of re-association
mechanism may be utilized by the numerous anchorless proteins of streptococci, but
further investigation is required. The enolase and GAPDH of Lactobacillus crispatus
bind to the lipoteichoic acids on the bacterial surface in a pH-dependent manner,
demonstrating for the first time a mechanism of glycolytic enzyme binding to the
bacterial cell wall [130].
5

The development of vaccines against streptococcal infection
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Traditionally, vaccines designed to prevent bacterial infection have been based on
strategies including: 1) whole-cell vaccines containing heat-killed pathogens; 2) live
attenuated vaccines constructed via inactivation of bacterial genes responsible for
essential metabolic functions or pathogenicity; 3) toxoid-based preparations; 4)
polysaccharides conjugated to suitable carrier proteins; and 5) subunit vaccines
containing either a) whole proteins (purified or recombinant), b) minimal peptide
epitopes, or c) cell wall and capsule antigens identified using biochemical, serological,
microbiological, or genetic techniques. Such approaches were time-consuming, often
taking many years or decades, and often failed when pathogens were difficult to
culture in vitro [131]. However, a new era of vaccine development technology has
emerged, aided by whole genome sequencing, bioinformatics, proteomics, and DNA
microarrays. Such technologies have allowed rapid discovery and identification of
putative virulence factors, surface-associated proteins and vaccine candidates.
The development of human streptococcal vaccines is challenging, facing
obstacles such as the occurrence of many unique serotypes, antigenic variation within
the same serotype, differences in geographical distribution of serotypes, and the
production of antibodies cross-reactive with human tissue which can lead to host autoimmune disease. Streptococcal disease is a continuing worldwide problem, occurring
in both developed and developing regions; thus the imperative for efficacious vaccines
to prevent streptococcal disease is high. Furthermore, whilst antibiotics continue to be
used to control streptococcal infection, there is increasing concern that such use, and
particularly over-use, leads to the emergence of resistant strains [58, 132, 133].
Additionally, streptococci may avoid the effect of antibiotics via intracellular invasion
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[134]. Although there are many candidate antigens and vaccine preparations under
investigation, currently, for all streptococcal species, there are only two licensed
human vaccines for use against pneumococcal infection.
5.1

Pnuemococcal vaccines

Although the two licensed S. pneumoniae vaccine preparations, comprising a
conjugate heptavalent and a 23-valent vaccine, have been successful in reducing the
incidence of streptococcal pneumonia and invasive pneumococcal disease caused by
serotypes incorporated in the vaccine preparation [135-139], these have no protective
effects against heterologous serotypes. Additionally, the 23-valent vaccine elicits a Tcell independent immune response and is thus not suitable for use in children under 2
years old or immunocompromised individuals. Comprehensive reviews of the different
conjugate pneumococcal vaccine formulations and human clinical trials have been
published by Wuoiimaa & Kayhty [140] and Oosterhuis-Kafeja et al. [135].
Pneumococci are genetically very flexible and can undergo natural transformation in
order to obtain new phenotypic traits. Recombination events at operon(s) encoding
capsule components can result in serotype switching, conferring the ability to evade
the host immune system [141-143]. Consequently, high levels of diversity and
evidence of capsule switching is observed in invasive pneumococcal isolates [144].
Given that the current capsule-based vaccines, both those licensed and those in preclinical and clinical development only protect against included serotypes, and that the
administration of such vaccines can result in serotype switching, it is thought that
protein-based vaccines may result in broader protection against S. pneumoniae
infection [145].
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Licensed pneumococcal vaccines and current vaccine candidates under
investigation are outlined in Table 2. Whilst several protein-based vaccine
preparations have been observed to protect in pre-clinical animal studies, and show
promise as vaccine formulations, very few have reached human clinical trials. In other
attempts to circumvent current problems associated with capsule polysaccharide
(CPS)-based vaccines, several groups have used proteomic and bioinformatic based
reverse engineering approaches to identify potential protein vaccine candidates. One
proteomic study identified two immunogenic proteins, FBA and GAPDH, which were
observed to protect against heterologous mucosal murine challenge [44]. A
bioinformatics based study utilized an in silico whole genome screening approach to
identify six vaccine antigens observed to protect against systemic challenge [146].
Such techniques show promise for the identification of efficacous vaccine candidates.
5.2

Group A streptococcal vaccine development

Currently there is no licensed vaccine to prevent group A streptococcal infection.
Many surface-associated proteins have been identified and are under investigation as
vaccine candidates (Table 3). GAS vaccinology has primarily focussed on the major
virulence factor, the M protein. However, several factors have hampered the
development of M protein-based vaccines such as the large number of unique M
serotypes, the potential antigenic variation within a serotype due to the continual
evolution of M protein [147], and the presence of cross-reacting epitopes which may
trigger post-infective immune sequelae [148]. Futhermore, circulating GAS strains can
rapidly be replaced by a new set of strains [149, 150]. As a consequence, N-terminal
multivalent M protein vaccine preparations may need to be continuously reformulated
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in order to protect against current circulating strains. On the other hand, non-M protein
GAS vaccine candidates are generally highly conserved and have not been observed to
result in the generation of cross-reactive antibodies. Several non-M protein vaccine
candidates have been extensively investigated and shown to be protective in preclinical animal studies (Table 3), although, to our knowledge, none of these have
reached human clinical trials.
M proteins are an obvious target for vaccine development as they are known to
be a major virulence factor in GAS and have elicited protective immunity in several
studies. Early studies involving vaccination of humans with crude M protein
preparations followed by administration of live GAS to the pharynx effectively
protected against GAS pharyngeal colonization [151-153], but one study noted an
increased incidence of rheumatic fever in vaccinated versus unvaccinated control
children [154]. This significantly hampered the development of whole M proteinbased vaccines. Since then, a number of vaccine development studies have targeted the
C-terminal repeat region peptides, conserved amongst all serotypes [155, 156]; whilst
other studies have focussed on polypeptides derived from the serotype specific Nterminal repeats [157-162]. One group has developed a hexavalent vaccine containing
protective N-terminal M protein fragments from six serotypes. The included serotypes
were selected due to a frequent association with pharyngitis and acute rheumatic fever
[162, 163]. This hybrid vaccine has been observed to generate high titre opsonising
antibodies in rabbits [162] and to protect against murine mucosal challenge [164].
Recently, the vaccine was tested in phase I clinical trials and was found to produce a
statistically significant increase in antibody titre for all six M protein fragments, with
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five of the six serotypes being opsonised by the resulting anti-sera [163]. Additionally,
there was no evidence the antibodies were cross-reactive with human tissue [163].
Although this vaccine was successful in phase I clinical trials, the major shortcoming
of this hexavalent vaccine is that it only offers protection against six of an estimated
120 GAS M-types. In an attempt to broaden the protection, a multivalent vaccine
containing variable amino terminal fragments of 26 different M proteins was produced
using recombinant techniques [165]. Following immunisation of rabbits, type-specific
antibodies raised against 25 of the 26 M protein fragments in the vaccine were
detected and none of these antibodies cross-reacted with host tissue [165].
Additionally, this vaccine preparation was observed to be safe and immunogenic in
phase I clinical trials [166]. Although this vaccine preparation shows promise for the
prevention of GAS infection, it is likely a vaccine protective against all serotypes will
be necessary for the eradication of GAS infection and disease.
In recent times, several proteomic studies of GAS have been carried out with
the aim of identifying putative vaccine candidates. One such proteomic study, based
on 2-DE and MALDI-TOF MS, identified 66 novel cell wall-associated proteins in
three different strains of GAS [59]. Thirty-three proteins were observed to be
immunoreactive with human antisera and 23 were suggested to be surface-exposed.
Due to this surface localization and immunoreactivity data, such proteins may be
suitable vaccine candidates. A proteomic trypsin digest of the cell-surface was utilised
by Severin et al., in which a total of 79 surface-proteins were identified, 33 of which
were novel surface-associated proteins in GAS [40]. These proteins are yet to be tested
as vaccine candidates in pre-clinical animal studies. Rodríguez-Ortega et al. identified
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14 surface-exposed proteins which were tested for protection in a murine disease
model. One of these antigens, Spy0416, elicited protection following heterologous
mucosal challenge [39]. Such proteomics-based screening approaches may result in
the identification of vaccine candidates efficacious against GAS infection.
5.3

Group B streptococcal vaccine development

Like GAS, there is no commercial vaccine available to prevent S. agalactiae (GBS)
infection. Whilst several vaccine candidates, both CPS and protein-based, are currently
under investigation (Table 4), one of the biggest hurdles for GBS vaccinology is the
legal liabilities of immunizing pregnant women in clinical trials, in which any adverse
outcomes could be linked to the experimental vaccine [167]. Of the current vaccine
candidates under development, conjugated CPS-based vaccines have been found to be
protective and immunogenic for vaccine strains [168-175], but are costly due to
individual conjugation of each CPS to the carrier protein. Protein-based vaccines are a
potentially cheaper alternative and may offer broader protection against all nine
circulating serotypes.
Candidate GBS protein antigens have been identified using various proteomic
and genomic screening methods. In a proteomic study of a GBS surface extract, 27
proteins were identified [43]. Two of these proteins, OCT and PGK, were observed to
confer a degree of protection in a neonatal murine infection model, and thus warrant
further investigation as GBS vaccine candidates. More recently, the same research
group used an alkaline phosphatase-based genetic screening method to identify outer
surface proteins. Two of the identified proteins, Pho2-2 and Pho3-1 (a yutD
homologue and an ABC transporter subunit, respectively), protected against
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heterologous subcutaneous challenge in a rat neonatal disease model [60]. Multigenomic screening studies have also been utilized to identify potential GBS vaccine
candidates. One group identified and tested a combination of four proteins, comprising
surface immunogenic protein and three other putative surface-proteins, which were
found to elicit protection in a neonatal murine disease model [50]. Furthermore, the
combination of these proteins was found to protect against representative strains of all
nine serotypes.
5.4

S. mutans vaccine development

Several surface antigens of S. mutans, the chief causative agents of dental caries, are
also under investigation as vaccine candidates (Table 5). One of the limiting factors in
the development of a vaccine to prevent dental caries is that it is a non-life-threatening
disease and thus has a lower financial priority [176]. To date, limited proteomics
studies have been performed on oral pathogens such as S. mutans and S. sobrinus, and
those conducted primarily focus on growth under differing conditions rather than the
identification of putative vaccine candidates. Refer to Macarthur & Jacques [177] for a
review on the proteomic analysis of oral pathogens.
5.5

Streptococcal vaccine development: future prospects

Whilst there are many current vaccine candidates and newly emerging proteomics-based
technologies leading to the identification of new candidates for S. pneumoniae, S.
pyogenes and S. agalactiae, tested vaccine candidates for invasive zoonotic streptococcal
strains such as S. suis or S. dysgalactiae subsp equisimilis and zooepidemicus are rare.
Proteomic approaches may yield candidate vaccine antigens suitable for protection
against human infection of these species. Although there are several streptococcal
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vaccine preparations undergoing human clinical trials, the majority are designed
predominantly to protect against strains in US and European populations. As the
geographical distribution of strains is highly variable [178, 179], such preparations are
often unsuitable for use in regions such as Asia, Africa and Oceania. If safe and
protective universal vaccine candidates for streptococcal species can be trialed that elicit
protection against all serotypes in humans, this would represent a major advance in
human health.
6

Conclusion

The growing body of streptococcal proteomic data illustrates the usefulness of a
proteomics-based approach in analyzing the cell surface topology of Gram-positive
cocci, which lays the foundation for the future identification of novel virulence
determinants, therapeutic agents and vaccine candidate antigens.
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Figure legend
Figure 1. Protein export pathways in Streptococcus. Ribosomally synthesized proteins
can be sorted to various destinations. A) via the Sec pathway (proteins containing Nterminal Sec-type signal peptide), B) via the TAT pathway (proteins containing twin
arginine (RR/KR) signal peptides), C) via the pili-specific pathway, D) via the ExPortal,
or E) via unknown export mechanisms (anchorless proteins).
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Table 1 Clinical manifestions of human infection by pathogenic streptococcal species
Species
group
None

Lancefield
Group
Group A

None

Group B

Species
S. pyogenes

S. agalactiae

Clinical manifestations of human Infection
infection
group
pharyngitis, pyoderma, erysipelas, HP
bacteremia, septicemia,
necrotising fasciitis, meningitis,
pneumonia, septic arthritis,
streptococcal toxic shock
syndrome, scarlet fever, rheumatic
feverb, glomerulonephritisb,
reactive arthritisb, autoimmune
neuropsychiatric disordersb
Invasive disease in neonates (<6
days old): septicemia, pneumonia,
meningitis, cellulites,
osteomyelitis, septic arthritis

REFS
[2, 3]

HP

[4-7,
180]

HP

[8, 9,
181,
182]

Invasive disease in neonates (6 to
90 days old): meningitis,
bacteremia, necrotising fasciitis
Perinatal disease: mild urinary
tract infection, puerperal sepsis,
chorioamnionitis, endometirosis,
cystitis, pyelonephritis,
bacteremia, may trigger pre-term
labour
otitis media, pneumonia,
meningitis, septicemia, pleural
empyema, septic arthritis, acute
conjunctivitis

S. mitis

Viridans

S. pneumoniae

S. anginosusa

Viridans

S. anginosus
S. constellatus
S. intermedius

bacteremia, endocarditis,
septicemia, meningitis
(particularly S. anginosus), abscess
(particularly S. constellatus),
respiratory infections (particulary
S. intermedius) including
pneumonia, pleural empyema and
pulmonary abscess

CO

[16,
18, 19,
183186]

S. mutans

Viridans

S. mutans
S. criceti
S. rattus
S. sobrinus

dental caries, bacteremia,
endocarditis, septicemia

CO

[10,
11,
187,
188]

S. salivarius

None

S. salivarius,
S. vestibularis

bacteremia, endocarditis

CO

[189191]

S. mitis or
S. sanguis

Viridans

S. mitis
S. oralis

throat infection, bacteremia,
endocarditis (primarily caused by

CO

[11,
17,
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S. sanguis
S. gordonii
S. cristatus
S. parasanguis

S. sanguis), septicemia

189,
191196]

None

None

S. sinensis

bacteremia, endocarditis

CO

[184,
197,
198]

S. anginosusa

Viridans

S. constellatus
subsp. pharyngis

pharyngitis

CO

[199]

S.
dysgalactiae

Group C
and G

S. dysgalactiae
subsp. equisimilis,
S. equi subsp.
zooepidemicus

pharyngitis, bacteremia,
septicemia, septic arthritis,
endocarditis, meningitis (S.
zooepidemicus only), pneumonia
(S. zooepidemicus only), toxic
shock syndrome,
glomerulonephritisb

ZO

[14,
200205]

S. bovis

Group D

S. bovis
S. equinus
S. infantarius
S. gallolyticus
S. lutetiensis
S. macedonicus
S. pasteuriana

endocarditis, bacteremia,
meningitis, septicemia

ZO

[206220]

ZO

[24]

S. bovis and S. infantarius are
associated with severe
inflammatory gastrointestinal
disease and with a potential role in
colon carcinogenesis
soft tissue infection, urinary tract
infection, bacteremia, septicemia,
bone infection, pneumonia

None

Group G

S. canis

None

Group E,
P, U, V

S. porcinus

wound infection, urogenital tract
infections in women, implicated
in pregnancy complications

ZO

[22,
221,
222]

None

None

S. suis

meningitis, sepsis, toxic shock
syndrome, arthritis, enteritis,
pneumonia, endocarditis,
deafnessb

ZO

[20,
223,
224]

None

None

S. iniae

bacteremic cellulites, arthritis,
endocarditis, bacteremic
osteomyelitis

ZO

[21,
225]

None

None

S. acidominimus

endocarditis, meningitis,
pericarditis, abscess, pneumonia

ZO

[226229]

None

None

S. gallinaceus

bacteremia

ZO

[23]

Footnotes and abbreviations: a) the S. anginosus group was previously known as the S. milleri group; b) as sequelae;
REFS, References; HP, common human pathogen; CO, commensal species causing opportunistic infection in humans;
ZO, zoonotic streptococcal species causing opportunistic infection in humans.
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Table 2 Licensed pneumococcal vaccines and vaccine candidates under investigation
Antigen
Function
Comment
Pneumococcus (Streptococcus pneumoniae)
Polysaccharide-based
Anti7-valent
T-cell-dependent response (immunological
phagocytic
(Prevnar)
memory). Shown to induce serotype
virulence
redistribution. Costly.
factor,
9-valent and
Reduces incidence of disease. Safe and
most CPS
11-valent
immunogenic. Only protects against limited
conjugated
serotypes.
to
Non-conjugated, thus cheaper. T-cell23-valent
DT mutant
independent, not effective in children less than
(Pneumovax)
two years.

Phase

L
(2000)
II /III

L
(1983)

REFS
[136, 143,
230-232]
[233-236]

[138, 139]

Protein-based
Surface protein
A (PspA)

Complement
inactivation

Protects against systemic infection. Safe and
immunogenic. May induce cross-reactive
antibodies.

P
I

[237-239]

Surface
adhesin A

Metal
binding

Protects against mucosal and systemic
challenge.

P

[240-243]

Surface
protein C

Adherence,
colonization

Protects against mucosal and systemic
challenge. Not present in all strains. Highly
variable.

Protective
protein A

Surfaceexposed

Intranasal immunization of mice reduced
colonization following heterologous mucosal
challenge.

P

[246]

6PGD

Adhesin

Protection against heterologous mucosal
challenge.

P

[247]

Protection against systemic homologous
challenge.

P

[248, 249]

As stated

Enhanced protection following mucosal and
systemic challenge, multiple antigens may
broaden protection.

P

[250, 251]

Pneumolysin
(PdB)

Hemolysin

Highly conserved sequence. Toxic for humans.
Non-toxic mutants best as a vaccine carrier
molecule.

P

[252-257]

Histidine
triad proteins

C3degrading,
unknown

Varying protection against heterologous
mucosal or systemic challenge.

P

[258-260]

Neuraminidase

Glycoside
hydrolase

Increased survival time and decreased
colonization following mucosal challenge.

P

[261, 262]

Autolysin

Degrades
cell wall

P

[263, 264]

Pilus subunits

Adhesion

Protection following systemic challenge.
Limited protection following mucosal
challenge.
Active and passive protection against challenge.

P

[265]

PiuA
PiaA

and Iron uptake

Multi-antigen
PspA, PsaA,
PdB

P

[244, 245]
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and
colonization

Expression restricted to a subset of strains.

Abbreviations: CPS, polysaccharide capsule; DT, diphtheria toxin; 6PGD, 6-Phosphogluconate
dehydrogenase; PspA, Pneumococcal surface protein A; PsaA, Pneumococcal surface adhesin A; PdB,
pneumolysin toxoid; P, Pre-clinical; I, Phase I clinical trial; II, Phase II clinical trial; III, Phase III clinical
trial; L, Licensed REFS, references.
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Table 3 Group A Streptococcal vaccine candidates under investigation
Antigen
Function
Comment
Group A Streptococcus (Streptococcus pyogenes)
Protein-based
Whole
Mucosal immunization reduces homologous
M protein
colonization in humans. Increase of ARF in
vaccinated subjects.
Surface

Phase

REFS

I

[151-154]

Peptides protect against mucosal heterologous
challenge. Systemic protection not investigated.
6- and 26-valent immunogenic and safe in
humans. Designed for US, may not protect in
other regions.
Cleaves C5a Reduced colonization following mucosal
(complement) challenge. Serotype independent protection.

P
P
I/II

[155,
266-269]
[160-166,
270]

P

[271-273]

FbaA

Fibronectinbinding

Protects against homologous systemic infection.
Expression restricted to a subset of strains.

P

[274]

FBP54

Fibronectinbinding

Protection following systemic challenge.
Expression restricted to a subset of strains.

P

[275]

Group
A
Carbohydrate

Antiopsonisation

Protects against mucosal and systemic challenge.
Cross-reacts with host tissues.

P

[276-278]

Protein
F1/SfbI

Fibronectinbinding

Mucosal immunization protects against
heterologous mucosal (not systemic) infection.

P

[279-281]

R18 Protein

Surfaceassociated

Passive protection against systemic infection.
Expression restricted to subset of strains.

P

[282]

Serum
Opacity
Factor/SfbII

Serum
opacification

Protection against systemic (not mucosal)
challenge. Expression limited to subset of strains.

P

[283,
284]

Rabbits protected against challenge. Expression
restricted to a subset of strains.

P

[285,
286]

M protein
C repeat
M protein
multivalent
C5a
Peptidase

SpeA
SpeC

adhesin,
antiphagocytic

and Pyrogenic
exotoxins

SpeB

Protease

Mice protected against systemic heterologous
challenge.

P

[287]

Sib35

Ig-binding

Protection against homologous systemic
challenge.

P

[288]

Spa

Surfaceassociated

Passive protection against systemic challenge.

P

[289]

Abbreviations: ARF, acute rheumatic fever; FbaA, Fibronectin-binding protein A; FBP54, Fibronectinbinding protein 54; Spe, Streptococcal pyrogenic exotoxin; Sib35, Streptococcal Ig binding protein; Spa,
Streptococcal protective antigen; P, Pre-clinical; I, Phase I clinical trial; II, Phase II clinical trial.
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Table 4 Group B Streptococcal vaccine candidates under investigation
Antigen
Function
Comment
Group B Streptococcus (Streptococcus agalactiae)
Based on Polysaccharide Capsule (CPS)
Type III
Safe and well tolerated but only 63%
polysaccharide
recipients responded. Immunogenicity must be
improved.
The
capsule
is
CPS-TT
Vast improvement in immunogenicity. Only
an important
conjugate
provides type-specific protection.
virulence
factor and
there are nine
Multivalent
Protective in murine neonatal model. Well
distinct
CPS-TT
tolerated in humans, but preparing individual
capsule types
conjugates is costly.
identified.
Alternative carrier proteins include: C protein,
Non-TT
C5a peptidase, diphtheria toxin, hepatitis B
conjugate CPS
core antigen.
Protein-based
C protein
(α and β)

Phase

REFS

I

[173]

P
I

[168, 169,
171, 172,
174, 175,
290-295]

P
I

[170, 296]

P

[297-300]

Surfaceassociated

Passive protection against systemic infection.
β protective in neonatal mice. Limited
expression.

P

[301-303]

BPS

Surfaceassociated

Mice protected from heterologous challenge.
Murine neonatal immunization model not
explored.

P

[304]

C5a peptidase

Cleaves C5a

Highly conserved. Immunization resulted in
enhanced clearance following mucosal
challenge.

P

[272, 300,
305]

(complement)

Fbs protein

Surfaceassociated

Active and passive protection against systemic
challenge. Expression restricted to a subset of
strains.

P

[306]

Leucine-rich
repeat protein

Surfaceassociated

Found in strains representing all nine
serotypes. Protects against homologous
systemic challenge.

P

[307]

Pho2-2 and
Pho3-1

Surfaceassociated

Limited knowledge of proteins function.
Protection against subcutaneous challenge in
neonatal rat model.

P

[60]

Sip

Surfaceassociated

Found on all serotypes. Mice protected against
heterologous systemic challenge.

P

[308, 309]

R28 (Alp3)

Surfaceassociated

Protection against systemic challenge
following passive and active immunization.

P

[282, 310]

Rib protein

Surfaceassociated

Protection following mucosal challenge and
systemic heterologous challenge.

P

[311-313]

Abbreviations: CPS, Polysaccharide capsule; TT, Tetanus toxoid; BPS, Group B protective surface
protein; Sip, Surface immunogenic protein; Rib, Resistance to proteases, immunity, group B; P, Preclinical; I, Phase I clinical trial.
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Table 5 Streptococcus mutans vaccine candidates under investigation
Antigen
Function
Streptococcus mutans
Antigen I/II
Surface
adhesin

Comment

Phase

REFS

Active and passive immunization of animals and
humans resulted in decreased oral colonization.

P

[314-321]

Glucosyltrans
fe-rase

Synthesis of
glucans

Reduced colonization following active and
passive immunization. Immunogenic, well
tolerated in humans.

P

Glucanbinding
proteins
GTF and
Antigen I/II

Receptor for
glucans

Active and passive immunization reduced dental
caries in rats.

P

[332-335]

As above

Significant reduction in colonization following
oral challenge of mice.

P

[336]

I
[322-331]

I

Abbreviations: GTF, Glucosyltransferase; P, Pre-clinical; I, Phase I clinical trial.
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